ABSTRACT
Genetic research into Atrial Fibrillation (AF) and Myocardial Infarction (MI) has predominantly concentrated on contrasting afflicted individuals with their healthy counterparts. However, this approach lacks granularity, overlooking the subtleties within patient populations. In this study, we explore the distinction between AF and MI patients experiencing only single events to those experiencing recurrent events. Integrating hospital records, questionnaire data, clinical measurements, and genetic data from more than 500, 000 HUNT and UKBB participants in our analysis, we compare the two groups for both clinical and genetic characteristics with GWAS meta-analyses, PheWAS-analyses, and gene co-expression networks. We find that the two groups of patients differs in both clinical characteristics and genetic risk. More specifically, recurrent AF patients are significantly younger with a better baseline health, in terms of lower cholesterol and blood pressure, than the single AF patients. The GWAS meta-analysis results indicate that recurrent AF patients seem to have a greater genetic risk of recurrent events and the PheWAS-analysis and gene co-expression network analyses highlight differences in the diseases and genetic functions associated to the set of SNPs and genes for to each group. In contrast, we find that for MI patients experiencing single events are significantly younger and have a better baseline health, yet they exhibit higher genetic risk. The GWAS meta-analysis identifies mostly genetic regions uniquely associated with single MI, and the PheWAS-analysis and gene co-expression networks support the genetic differences between these two groups.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by K. G. Jebsen Foundation for Grant SKGJ-MED-015
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Norwegian Data Inspectorate and the Regional Ethics Committee for Medical Research in Norway (REK: 2014/144)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
